View ValuationBiofrontera 将来の成長Future 基準チェック /06現在、 Biofronteraの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 3 analysts covering Biofrontera expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.60m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Price Target Changed • Nov 25Price target decreased to €5.50Down from €6.80, the current price target is an average from 3 analysts. New target price is 206% above last closing price of €1.80. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.21 next year compared to a net loss per share of €0.24 last year.Major Estimate Revision • Nov 25Consensus EPS estimates fall to -€0.21The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €30.4m to €28.7m. Losses expected to increase from -€0.14 to -€0.21. Biotechs industry in Germany expected to see average net income growth of 4.0% next year. Consensus price target down from €6.80 to €5.50. Share price fell 4.0% to €1.80 over the past week.Breakeven Date Change • Nov 25No longer forecast to breakevenThe 3 analysts covering Biofrontera no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.50m in 2023. New consensus forecast suggests the company will make a loss of €1.50m in 2023.Price Target Changed • Jun 18Price target increased to €6.80Up from €5.40, the current price target is an average from 3 analysts. New target price is 134% above last closing price of €2.91. Stock is down 7.8% over the past year.Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.38 to -€0.31 per share. Revenue forecast unchanged from €29.4m at last update. Biotechs industry in Germany expected to see average net income growth of 2.4% next year. Consensus price target of €6.90 unchanged from last update. Share price rose 14% to €2.69 over the past week.すべての更新を表示Recent updatesお知らせ • May 02Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 20Full year 2025 earnings released: €0.62 loss per share (vs €0.72 loss in FY 2024)Full year 2025 results: €0.62 loss per share. Revenue: €13.2m (down 39% from FY 2024). Net loss: €6.81m (loss widened 57% from FY 2024).お知らせ • Feb 09+ 3 more updatesBiofrontera AG to Report Fiscal Year 2025 Results on Mar 31, 2026Biofrontera AG announced that they will report fiscal year 2025 results on Mar 31, 2026New Risk • Dec 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (€16.2m market cap, or US$19.1m).お知らせ • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.分析記事 • Sep 12Will Biofrontera (ETR:B8FK) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (€14.3m market cap, or US$16.8m).Reported Earnings • Jun 03First quarter 2025 earnings released: EPS: €0.11 (vs €0.84 loss in 1Q 2024)First quarter 2025 results: EPS: €0.11 (up from €0.84 loss in 1Q 2024). Revenue: €5.77m (up 55% from 1Q 2024). Net income: €678.0k (up €3.39m from 1Q 2024). Profit margin: 12% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 17Full year 2024 earnings released: €0.72 loss per share (vs €0.12 loss in FY 2023)Full year 2024 results: €0.72 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €21.7m (down 33% from FY 2023). Net loss: €4.35m (loss widened €3.98m from FY 2023). Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Over the last 3 years on average, earnings per share has fallen by 55% per year whereas the company’s share price has fallen by 52% per year.お知らせ • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025Reported Earnings • Dec 01Third quarter 2024 earnings released: €0.15 loss per share (vs €1.05 loss in 3Q 2023)Third quarter 2024 results: €0.15 loss per share (improved from €1.05 loss in 3Q 2023). Revenue: €3.52m (down 50% from 3Q 2023). Net loss: €931.0k (loss narrowed 70% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance.お知らせ • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.分析記事 • Oct 13Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For ExcitementBiofrontera AG ( ETR:B8FK ) shareholders would be excited to see that the share price has had a great month, posting a...New Risk • Oct 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.0m free cash flow). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.4m market cap, or US$16.0m).Reported Earnings • Oct 02Second quarter 2024 earnings released: €0.023 loss per share (vs €0.12 profit in 2Q 2023)Second quarter 2024 results: €0.023 loss per share (down from €0.12 profit in 2Q 2023). Revenue: €3.49m (down 71% from 2Q 2023). Net loss: €2.64m (down €2.97m from profit in 2Q 2023).お知らせ • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024お知らせ • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.New Risk • Jun 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€16.7m market cap, or US$18.0m).Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €2.47, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 96% over the past three years.Reported Earnings • Jun 04First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023)First quarter 2024 results: €0.04 loss per share (improved from €1.05 loss in 1Q 2023). Revenue: €3.71m (down 36% from 1Q 2023). Net loss: €2.71m (loss narrowed 22% from 1Q 2023).分析記事 • May 21Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%The Biofrontera AG ( ETR:B8FK ) share price has fared very poorly over the last month, falling by a substantial 47...お知らせ • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024Reported Earnings • May 01Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.77 loss in FY 2022). Revenue: €32.2m (up 25% from FY 2022). Net loss: €369.0k (loss narrowed 99% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024分析記事 • Mar 07Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price PlungeBiofrontera AG ( ETR:B8F ) shareholders that were waiting for something to happen have been dealt a blow with a 30...分析記事 • Feb 19We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023お知らせ • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023お知らせ • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.お知らせ • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023お知らせ • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.お知らせ • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen GermanyBreakeven Date Change • Jan 01Forecast to breakeven in 2024The 3 analysts covering Biofrontera expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.60m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.分析記事 • Dec 07Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This YearShareholders will probably not be too impressed with the underwhelming results at Biofrontera AG ( ETR:B8F ) recently...Price Target Changed • Nov 25Price target decreased to €5.50Down from €6.80, the current price target is an average from 3 analysts. New target price is 206% above last closing price of €1.80. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.21 next year compared to a net loss per share of €0.24 last year.Major Estimate Revision • Nov 25Consensus EPS estimates fall to -€0.21The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €30.4m to €28.7m. Losses expected to increase from -€0.14 to -€0.21. Biotechs industry in Germany expected to see average net income growth of 4.0% next year. Consensus price target down from €6.80 to €5.50. Share price fell 4.0% to €1.80 over the past week.Breakeven Date Change • Nov 25No longer forecast to breakevenThe 3 analysts covering Biofrontera no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.50m in 2023. New consensus forecast suggests the company will make a loss of €1.50m in 2023.Reported Earnings • Nov 19Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €5.38m (up 14% from 3Q 2020). Net loss: €5.39m (loss narrowed 17% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 20Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: €7.62m (down 21% from 2Q 2020). Net loss: €4.00m (loss widened €3.92m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Price Target Changed • Jun 18Price target increased to €6.80Up from €5.40, the current price target is an average from 3 analysts. New target price is 134% above last closing price of €2.91. Stock is down 7.8% over the past year.分析記事 • Jun 08Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.38 to -€0.31 per share. Revenue forecast unchanged from €29.4m at last update. Biotechs industry in Germany expected to see average net income growth of 2.4% next year. Consensus price target of €6.90 unchanged from last update. Share price rose 14% to €2.69 over the past week.Reported Earnings • May 12First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020)The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: €5.48m (down 15% from 1Q 2020). Net loss: €4.88m (loss narrowed 11% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Price Target Changed • May 11Price target decreased to €6.90Down from €10.33, the current price target is an average from 3 analysts. New target price is 190% above last closing price of €2.38. Stock is down 18% over the past year.分析記事 • Apr 14Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportLast week, you might have seen that Biofrontera AG ( ETR:B8F ) released its yearly result to the market. The early...Reported Earnings • Apr 14Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €30.3m (down 2.9% from FY 2019). Net loss: €13.0m (loss widened 77% from FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 10Price target raised to €10.33Up from €8.07, the current price target is an average from 3 analysts. The new target price is 303% above the current share price of €2.57. As of last close, the stock is down 38% over the past year.Executive Departure • Mar 02CFO & Member of the Executive Board has left the companyOn the 28th of February, Thomas Schaffer's tenure as CFO & Member of the Executive Board ended after 7.8 years in the role. As of December 2020, Thomas personally held 22.02k shares (€67k worth at the time). Thomas is the only executive to leave the company over the last 12 months.Is New 90 Day High Low • Feb 23New 90-day low: €2.82The company is down 10.0% from its price of €3.12 on 25 November 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.81 per share.Price Target Changed • Jan 30Price target raised to €8.55Up from €7.93, the current price target is an average from 3 analysts. The new target price is 163% above the current share price of €3.25. As of last close, the stock is down 37% over the past year.Is New 90 Day High Low • Jan 11New 90-day high: €3.37The company is up 3.0% from its price of €3.28 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.94 per share.Is New 90 Day High Low • Dec 12New 90-day low: €2.83The company is down 24% from its price of €3.74 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.69 per share.Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.11 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: €4.71m (down 8.6% from 3Q 2019). Net loss: €6.46m (loss narrowed 44% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 03New 90-day low: €2.87The company is down 33% from its price of €4.31 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €35.72 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biofrontera は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XTRA:B8FK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202513-7-4-4N/A9/30/202523-2N/AN/AN/A3/31/202524-1N/AN/AN/A12/31/2024121-3-3N/A9/30/2024180N/AN/AN/A6/30/202422-3-5-4N/A3/31/2024300N/AN/AN/A12/31/2023320-3-2N/A9/30/202329-9N/AN/AN/A6/30/202328-11-4-3N/A3/31/202325-20N/AN/AN/A12/31/202226-44-5-4N/A9/30/20223211N/AN/AN/A6/30/202231103333N/A3/31/20223015N/AN/AN/A12/31/202129383030N/A9/30/202128-16N/AN/AN/A6/30/202127-16-8-7N/A3/31/202129-12N/AN/AN/A12/31/202030-13-4-3N/A9/30/202033-17N/AN/AN/A6/30/202033-22-14-12N/A3/31/202031-10N/AN/AN/A12/31/201931-7-35-33N/A9/30/2019261N/AN/AN/A6/30/2019268N/A-28N/A3/31/201923-8N/AN/AN/A12/31/201821-9N/A-13N/A9/30/201819-14N/A-13N/A6/30/201816-15N/A-12N/A3/31/201814-16N/AN/AN/A12/31/201712-16N/A-13N/A9/30/201711-18N/A-16N/A6/30/20179-16N/A-16N/A3/31/20178-14N/A-15N/A12/31/20166-11N/A-10N/A9/30/20164-9N/A-8N/A6/30/20164-7N/A-6N/A3/31/20164-9N/A-8N/A12/31/20154-11N/A-10N/A9/30/20154-12N/A-10N/A6/30/20153-13N/A-10N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: B8FKの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: B8FKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: B8FKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: B8FKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: B8FKの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: B8FKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:49終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biofrontera AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Raymond MyersBenchmark CompanyTsvetan KintisheffFirst Berlin Equity Research GmbHThomas FlatenLake Street Capital Markets, LLC3 その他のアナリストを表示
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 3 analysts covering Biofrontera expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.60m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Price Target Changed • Nov 25Price target decreased to €5.50Down from €6.80, the current price target is an average from 3 analysts. New target price is 206% above last closing price of €1.80. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.21 next year compared to a net loss per share of €0.24 last year.
Major Estimate Revision • Nov 25Consensus EPS estimates fall to -€0.21The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €30.4m to €28.7m. Losses expected to increase from -€0.14 to -€0.21. Biotechs industry in Germany expected to see average net income growth of 4.0% next year. Consensus price target down from €6.80 to €5.50. Share price fell 4.0% to €1.80 over the past week.
Breakeven Date Change • Nov 25No longer forecast to breakevenThe 3 analysts covering Biofrontera no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.50m in 2023. New consensus forecast suggests the company will make a loss of €1.50m in 2023.
Price Target Changed • Jun 18Price target increased to €6.80Up from €5.40, the current price target is an average from 3 analysts. New target price is 134% above last closing price of €2.91. Stock is down 7.8% over the past year.
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.38 to -€0.31 per share. Revenue forecast unchanged from €29.4m at last update. Biotechs industry in Germany expected to see average net income growth of 2.4% next year. Consensus price target of €6.90 unchanged from last update. Share price rose 14% to €2.69 over the past week.
お知らせ • May 02Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 20Full year 2025 earnings released: €0.62 loss per share (vs €0.72 loss in FY 2024)Full year 2025 results: €0.62 loss per share. Revenue: €13.2m (down 39% from FY 2024). Net loss: €6.81m (loss widened 57% from FY 2024).
お知らせ • Feb 09+ 3 more updatesBiofrontera AG to Report Fiscal Year 2025 Results on Mar 31, 2026Biofrontera AG announced that they will report fiscal year 2025 results on Mar 31, 2026
New Risk • Dec 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (€16.2m market cap, or US$19.1m).
お知らせ • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.
分析記事 • Sep 12Will Biofrontera (ETR:B8FK) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (€14.3m market cap, or US$16.8m).
Reported Earnings • Jun 03First quarter 2025 earnings released: EPS: €0.11 (vs €0.84 loss in 1Q 2024)First quarter 2025 results: EPS: €0.11 (up from €0.84 loss in 1Q 2024). Revenue: €5.77m (up 55% from 1Q 2024). Net income: €678.0k (up €3.39m from 1Q 2024). Profit margin: 12% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 17Full year 2024 earnings released: €0.72 loss per share (vs €0.12 loss in FY 2023)Full year 2024 results: €0.72 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €21.7m (down 33% from FY 2023). Net loss: €4.35m (loss widened €3.98m from FY 2023). Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Over the last 3 years on average, earnings per share has fallen by 55% per year whereas the company’s share price has fallen by 52% per year.
お知らせ • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025
Reported Earnings • Dec 01Third quarter 2024 earnings released: €0.15 loss per share (vs €1.05 loss in 3Q 2023)Third quarter 2024 results: €0.15 loss per share (improved from €1.05 loss in 3Q 2023). Revenue: €3.52m (down 50% from 3Q 2023). Net loss: €931.0k (loss narrowed 70% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.
分析記事 • Oct 13Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For ExcitementBiofrontera AG ( ETR:B8FK ) shareholders would be excited to see that the share price has had a great month, posting a...
New Risk • Oct 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.0m free cash flow). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.4m market cap, or US$16.0m).
Reported Earnings • Oct 02Second quarter 2024 earnings released: €0.023 loss per share (vs €0.12 profit in 2Q 2023)Second quarter 2024 results: €0.023 loss per share (down from €0.12 profit in 2Q 2023). Revenue: €3.49m (down 71% from 2Q 2023). Net loss: €2.64m (down €2.97m from profit in 2Q 2023).
お知らせ • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024
お知らせ • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.
New Risk • Jun 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€16.7m market cap, or US$18.0m).
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €2.47, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 96% over the past three years.
Reported Earnings • Jun 04First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023)First quarter 2024 results: €0.04 loss per share (improved from €1.05 loss in 1Q 2023). Revenue: €3.71m (down 36% from 1Q 2023). Net loss: €2.71m (loss narrowed 22% from 1Q 2023).
分析記事 • May 21Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%The Biofrontera AG ( ETR:B8FK ) share price has fared very poorly over the last month, falling by a substantial 47...
お知らせ • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024
Reported Earnings • May 01Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.77 loss in FY 2022). Revenue: €32.2m (up 25% from FY 2022). Net loss: €369.0k (loss narrowed 99% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024
分析記事 • Mar 07Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price PlungeBiofrontera AG ( ETR:B8F ) shareholders that were waiting for something to happen have been dealt a blow with a 30...
分析記事 • Feb 19We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023
お知らせ • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023
お知らせ • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.
お知らせ • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023
お知らせ • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.
お知らせ • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen Germany
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 3 analysts covering Biofrontera expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.60m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
分析記事 • Dec 07Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This YearShareholders will probably not be too impressed with the underwhelming results at Biofrontera AG ( ETR:B8F ) recently...
Price Target Changed • Nov 25Price target decreased to €5.50Down from €6.80, the current price target is an average from 3 analysts. New target price is 206% above last closing price of €1.80. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.21 next year compared to a net loss per share of €0.24 last year.
Major Estimate Revision • Nov 25Consensus EPS estimates fall to -€0.21The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €30.4m to €28.7m. Losses expected to increase from -€0.14 to -€0.21. Biotechs industry in Germany expected to see average net income growth of 4.0% next year. Consensus price target down from €6.80 to €5.50. Share price fell 4.0% to €1.80 over the past week.
Breakeven Date Change • Nov 25No longer forecast to breakevenThe 3 analysts covering Biofrontera no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.50m in 2023. New consensus forecast suggests the company will make a loss of €1.50m in 2023.
Reported Earnings • Nov 19Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €5.38m (up 14% from 3Q 2020). Net loss: €5.39m (loss narrowed 17% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 20Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: €7.62m (down 21% from 2Q 2020). Net loss: €4.00m (loss widened €3.92m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Jun 18Price target increased to €6.80Up from €5.40, the current price target is an average from 3 analysts. New target price is 134% above last closing price of €2.91. Stock is down 7.8% over the past year.
分析記事 • Jun 08Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.38 to -€0.31 per share. Revenue forecast unchanged from €29.4m at last update. Biotechs industry in Germany expected to see average net income growth of 2.4% next year. Consensus price target of €6.90 unchanged from last update. Share price rose 14% to €2.69 over the past week.
Reported Earnings • May 12First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020)The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: €5.48m (down 15% from 1Q 2020). Net loss: €4.88m (loss narrowed 11% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Price Target Changed • May 11Price target decreased to €6.90Down from €10.33, the current price target is an average from 3 analysts. New target price is 190% above last closing price of €2.38. Stock is down 18% over the past year.
分析記事 • Apr 14Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportLast week, you might have seen that Biofrontera AG ( ETR:B8F ) released its yearly result to the market. The early...
Reported Earnings • Apr 14Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €30.3m (down 2.9% from FY 2019). Net loss: €13.0m (loss widened 77% from FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 10Price target raised to €10.33Up from €8.07, the current price target is an average from 3 analysts. The new target price is 303% above the current share price of €2.57. As of last close, the stock is down 38% over the past year.
Executive Departure • Mar 02CFO & Member of the Executive Board has left the companyOn the 28th of February, Thomas Schaffer's tenure as CFO & Member of the Executive Board ended after 7.8 years in the role. As of December 2020, Thomas personally held 22.02k shares (€67k worth at the time). Thomas is the only executive to leave the company over the last 12 months.
Is New 90 Day High Low • Feb 23New 90-day low: €2.82The company is down 10.0% from its price of €3.12 on 25 November 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.81 per share.
Price Target Changed • Jan 30Price target raised to €8.55Up from €7.93, the current price target is an average from 3 analysts. The new target price is 163% above the current share price of €3.25. As of last close, the stock is down 37% over the past year.
Is New 90 Day High Low • Jan 11New 90-day high: €3.37The company is up 3.0% from its price of €3.28 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.94 per share.
Is New 90 Day High Low • Dec 12New 90-day low: €2.83The company is down 24% from its price of €3.74 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.69 per share.
Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.11 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: €4.71m (down 8.6% from 3Q 2019). Net loss: €6.46m (loss narrowed 44% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 03New 90-day low: €2.87The company is down 33% from its price of €4.31 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €35.72 per share.